Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chiron Corporation
Nonexclusive HCV license granted to Boehringer Ingelheim
January 14th, 2004
Chiron Corporation (CHIR) announced that it has granted to Boehringer Ingelheim International GmbH a nonexclusive license for the research, development, and commercialization of small molecule therapeutics against hepatitis C virus (HCV) drug targets. Under the terms of the agreement, Boehringer Ingelheim would pay Chiron up-front license fees, milestone payments, and royalties on products. The specific financial terms and other details of the license were not disclosed. "This agreement is a further example of Chiron's strong commitment to making its technology widely available to companies working to find therapies for hepatitis C," said William G....
Source: Biotech Week (2004-01-14)
|
